PAVmed Historical Financial Ratios

PAVMZ Stock  USD 0.01  0.00  0.00%   
PAVmed Series is promptly reporting on over 99 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Average Payables of 2.1 M, Stock Based Compensation To Revenue of 4.32, Capex To Depreciation of 0.0784 or Ev To Sales of 22.81 will help investors to properly organize and evaluate PAVmed Series Z financial condition quickly.
  
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PAVmed Series Z. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

About PAVmed Financial Ratios Analysis

PAVmed Series ZFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate PAVmed Series investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on PAVmed financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across PAVmed Series history.

PAVmed Series Financial Ratios Chart

At this time, PAVmed Series' ROIC is fairly stable compared to the past year. Inventory Turnover is likely to rise to 12.51 in 2024, whereas PTB Ratio is likely to drop (0.58) in 2024.
Add Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Graham NumberShareholders Equity Per Share
Debt To EquityCapex Per Share
Graham Net NetAverage Receivables
Revenue Per ShareInterest Debt Per Share
Debt To AssetsEnterprise Value Over E B I T D A
Short Term Coverage RatiosPrice Earnings Ratio
Operating CyclePrice Book Value Ratio
Price Earnings To Growth RatioDays Of Payables Outstanding
Dividend Payout RatioPrice To Operating Cash Flows Ratio
Price To Free Cash Flows RatioPretax Profit Margin
Ebt Per EbitOperating Profit Margin
Effective Tax RateCompany Equity Multiplier
Long Term Debt To CapitalizationTotal Debt To Capitalization
Return On Capital EmployedDebt Equity Ratio
Ebit Per RevenueQuick Ratio
Dividend Paid And Capex Coverage RatioNet Income Per E B T
Cash RatioCash Conversion Cycle
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Fixed Asset TurnoverCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On Equity

Price To Sales Ratio

Price to Sales Ratio is figured by comparing PAVmed Series Z stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on PAVmed Series sales, a figure that is much harder to manipulate than other PAVmed Series Z multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Dividend Yield

Dividend Yield is PAVmed Series Z dividend as a percentage of PAVmed Series stock price. PAVmed Series Z dividend yield is a measure of PAVmed Series stock productivity, which can be interpreted as interest rate earned on an PAVmed Series investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.

Average Payables

The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.

Capex To Depreciation

The ratio of a company's capital expenditures to its depreciation expenses, indicating how much the company is investing in physical assets relative to the aging of existing assets.

Current Ratio

A liquidity ratio that measures a company's ability to pay short-term obligations or those due within one year. It compares a firm's current assets to its current liabilities.
Most ratios from PAVmed Series' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into PAVmed Series Z current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PAVmed Series Z. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
At this time, PAVmed Series' ROIC is fairly stable compared to the past year. Inventory Turnover is likely to rise to 12.51 in 2024, whereas PTB Ratio is likely to drop (0.58) in 2024.
 2010 2023 2024 (projected)
Dividend Yield3.31E-42.98E-42.65E-4
Price To Sales Ratio381.3812.1511.54

PAVmed Series fundamentals Correlations

0.820.050.770.30.970.530.820.710.051.00.53-0.09-0.970.450.88-0.970.7-0.09-0.360.06-0.840.11-0.360.75-0.31
0.820.030.670.340.720.281.00.550.030.860.28-0.23-0.70.180.66-0.920.910.03-0.270.08-0.81-0.1-0.270.56-0.16
0.050.030.030.110.080.340.030.061.00.050.34-0.46-0.050.290.05-0.040.020.03-0.4-0.06-0.030.02-0.40.05-0.47
0.770.670.030.320.690.250.670.510.030.80.24-0.2-0.640.160.61-0.830.840.06-0.250.07-0.98-0.1-0.250.52-0.3
0.30.340.110.320.280.020.340.580.110.310.0-0.26-0.240.05-0.17-0.310.350.75-0.110.17-0.35-0.87-0.11-0.13-0.06
0.970.720.080.690.280.690.720.80.080.950.690.02-0.980.640.89-0.90.58-0.21-0.50.15-0.750.18-0.50.83-0.43
0.530.280.340.250.020.690.280.740.340.51.00.02-0.60.970.66-0.440.13-0.57-0.860.39-0.280.4-0.860.86-0.8
0.821.00.030.670.340.720.280.550.030.860.28-0.23-0.70.180.65-0.920.910.03-0.270.08-0.81-0.1-0.270.56-0.16
0.710.550.060.510.580.80.740.550.060.70.730.02-0.70.730.53-0.660.45-0.04-0.620.41-0.56-0.18-0.620.7-0.52
0.050.031.00.030.110.080.340.030.060.050.34-0.46-0.050.290.05-0.040.020.03-0.4-0.06-0.030.02-0.40.05-0.47
1.00.860.050.80.310.950.50.860.70.050.5-0.12-0.950.410.86-0.990.76-0.06-0.350.06-0.870.07-0.350.74-0.31
0.530.280.340.240.00.691.00.280.730.340.50.02-0.60.970.66-0.440.12-0.58-0.860.39-0.270.42-0.860.86-0.8
-0.09-0.23-0.46-0.2-0.260.020.02-0.230.02-0.46-0.120.020.010.10.040.16-0.3-0.380.340.290.230.250.340.110.43
-0.97-0.7-0.05-0.64-0.24-0.98-0.6-0.7-0.7-0.05-0.95-0.60.01-0.53-0.890.89-0.530.140.37-0.040.7-0.20.37-0.760.32
0.450.180.290.160.050.640.970.180.730.290.410.970.1-0.530.56-0.340.02-0.56-0.820.34-0.180.34-0.820.78-0.71
0.880.660.050.61-0.170.890.660.650.530.050.860.660.04-0.890.56-0.830.52-0.52-0.440.03-0.670.56-0.440.9-0.41
-0.97-0.92-0.04-0.83-0.31-0.9-0.44-0.92-0.66-0.04-0.99-0.440.160.89-0.34-0.83-0.860.050.34-0.070.92-0.030.34-0.710.29
0.70.910.020.840.350.580.130.910.450.020.760.12-0.3-0.530.020.52-0.860.12-0.210.09-0.92-0.22-0.210.44-0.17
-0.090.030.030.060.75-0.21-0.570.03-0.040.03-0.06-0.58-0.380.14-0.56-0.520.050.120.42-0.19-0.06-0.870.42-0.640.36
-0.36-0.27-0.4-0.25-0.11-0.5-0.86-0.27-0.62-0.4-0.35-0.860.340.37-0.82-0.440.34-0.210.42-0.40.27-0.21.0-0.660.95
0.060.08-0.060.070.170.150.390.080.41-0.060.060.390.29-0.040.340.03-0.070.09-0.19-0.4-0.08-0.12-0.40.28-0.39
-0.84-0.81-0.03-0.98-0.35-0.75-0.28-0.81-0.56-0.03-0.87-0.270.230.7-0.18-0.670.92-0.92-0.060.27-0.080.110.27-0.570.28
0.11-0.10.02-0.1-0.870.180.4-0.1-0.180.020.070.420.25-0.20.340.56-0.03-0.22-0.87-0.2-0.120.11-0.20.52-0.23
-0.36-0.27-0.4-0.25-0.11-0.5-0.86-0.27-0.62-0.4-0.35-0.860.340.37-0.82-0.440.34-0.210.421.0-0.40.27-0.2-0.660.95
0.750.560.050.52-0.130.830.860.560.70.050.740.860.11-0.760.780.9-0.710.44-0.64-0.660.28-0.570.52-0.66-0.59
-0.31-0.16-0.47-0.3-0.06-0.43-0.8-0.16-0.52-0.47-0.31-0.80.430.32-0.71-0.410.29-0.170.360.95-0.390.28-0.230.95-0.59
Click cells to compare fundamentals

PAVmed Series Account Relationship Matchups

PAVmed Series fundamentals Accounts

201920202021202220232024 (projected)
Ptb Ratio(9.48)53.043.09(4.42)(0.55)(0.58)
Book Value Per Share(2.3)(0.15)15.371.84(3.32)(3.16)
Free Cash Flow Yield(0.41)(0.37)(0.22)(1.7)(1.75)(1.67)
Operating Cash Flow Per Share(6.63)(6.93)(7.85)(11.95)(7.2)(7.56)
Capex To Depreciation1.912.396.50.630.08250.0784
Pb Ratio(9.48)53.043.09(4.42)(0.55)(0.58)
Free Cash Flow Per Share(6.65)(6.95)(8.14)(12.21)(7.23)(7.59)
Roic(3.06)(1.3)(0.79)(3.72)7.147.5
Net Income Per Share(7.91)(10.86)(9.74)(17.06)(8.87)(9.32)
Payables Turnover0.0060460.0077550.181.343.593.77
Cash Per Share3.115.5415.347.22.723.54
Pocfratio(2.44)(2.71)(4.59)(4.7)(0.6)(0.57)
Interest Coverage(4.42)(437.61)(440.58)(71.48)(116.8)(122.64)
Capex To Operating Cash Flow(0.002037)(0.00251)(0.0362)(0.0217)(0.004651)(0.004883)
Pfcf Ratio(2.71)(4.58)(4.53)(0.59)(0.57)(0.6)
Days Payables Outstanding60.4K47.1K2.1K273.09101.5496.46
Income Quality0.480.770.610.720.810.51
Roe4.17(18.11)(0.82)10.461.191.13
Ev To Operating Cash Flow(2.86)(4.48)(2.79)(0.56)(1.13)(1.19)
Pe Ratio(2.27)(2.93)(3.79)(0.42)(0.46)(0.49)
Return On Tangible Assets(2.2)(1.74)(0.59)(2.0)(2.02)(2.13)
Ev To Free Cash Flow(2.85)(4.47)(2.7)(0.55)(1.13)(1.18)
Earnings Yield(0.44)(0.34)(0.26)(2.37)(2.15)(2.05)
Net Debt To E B I T D A(0.12)0.06411.380.0313(0.38)(0.36)
Current Ratio0.550.9510.931.070.450.43
Tangible Book Value Per Share(2.3)(0.15)14.981.26(3.52)(3.34)
Graham Number18.3912.151.1425.0138.5540.48
Shareholders Equity Per Share(1.9)0.611.93(1.63)(7.44)(7.07)
Debt To Equity(3.41)(2.13)8.05(3.48)(0.82)(0.78)
Capex Per Share0.01350.01740.280.260.03350.0657
Graham Net Net(2.79)(0.73)14.35(0.0259)(5.14)(4.88)
Interest Debt Per Share6.934.064.845.886.194.12
Debt To Assets0.931.120.770.621.331.09
Enterprise Value Over E B I T D A(2.29)(2.74)(2.03)(0.4)(0.78)(0.82)
Price Earnings Ratio(2.27)(2.93)(3.79)(0.42)(0.46)(0.49)
Price Book Value Ratio(9.48)53.043.09(4.42)(0.55)(0.58)
Price Earnings To Growth Ratio0.0665(0.0929)0.37(0.007909)0.01190.0125

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for PAVmed Stock Analysis

When running PAVmed Series' price analysis, check to measure PAVmed Series' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PAVmed Series is operating at the current time. Most of PAVmed Series' value examination focuses on studying past and present price action to predict the probability of PAVmed Series' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PAVmed Series' price. Additionally, you may evaluate how the addition of PAVmed Series to your portfolios can decrease your overall portfolio volatility.